Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Plasma Metabolomic Signatures Associated with Long-term Breast Cancer Risk in the SU.VI.MAX Prospective Cohort.

Lécuyer L, Dalle C, Lyan B, Demidem A, Rossary A, Vasson MP, Petera M, Lagree M, Ferreira T, Centeno D, Galan P, Hercberg S, Deschasaux M, Partula V, Srour B, Latino-Martel P, Kesse-Guyot E, Druesne-Pecollo N, Durand S, Pujos-Guillot E, Touvier M.

Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1300-1307. doi: 10.1158/1055-9965.EPI-19-0154. Epub 2019 Jun 4.

PMID:
31164347
2.
3.

NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer.

Lécuyer L, Victor Bala A, Deschasaux M, Bouchemal N, Nawfal Triba M, Vasson MP, Rossary A, Demidem A, Galan P, Hercberg S, Partula V, Le Moyec L, Srour B, Fiolet T, Latino-Martel P, Kesse-Guyot E, Savarin P, Touvier M.

Int J Epidemiol. 2018 Apr 1;47(2):484-494. doi: 10.1093/ije/dyx271.

PMID:
29365091
4.

Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts ¹H-NMR Spectroscopy.

Teilhet C, Morvan D, Joubert-Zakeyh J, Biesse AS, Pereira B, Massoulier S, Dechelotte P, Pezet D, Buc E, Lamblin G, Peoc'h M, Porcheron J, Vasson MP, Abergel A, Demidem A.

Metabolites. 2017 Sep 22;7(4). pii: E49. doi: 10.3390/metabo7040049.

5.

Metabolomics and transcriptomics demonstrate severe oxidative stress in both localized chemotherapy-treated and bystander tumors.

Morvan D, Demidem A.

Biochim Biophys Acta. 2014 Mar;1840(3):1092-104. doi: 10.1016/j.bbagen.2013.11.022. Epub 2013 Dec 1.

PMID:
24296419
6.

Normal human melanocytes exposed to chronic insulin and glucose supplementation undergo oncogenic changes and methyl group metabolism cellular redistribution.

Morvan D, Steyaert JM, Schwartz L, Israel M, Demidem A.

Am J Physiol Endocrinol Metab. 2012 Jun 1;302(11):E1407-18. doi: 10.1152/ajpendo.00594.2011. Epub 2012 Apr 3.

7.

Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.

Vialter A, Vincent A, Demidem A, Morvan D, Stepien G, Venezia ND, Rio PG.

Biochim Biophys Acta. 2011 Apr;1810(4):432-8. doi: 10.1016/j.bbagen.2010.12.001. Epub 2010 Dec 13.

PMID:
21147198
8.

Quantitative two-dimensional HRMAS 1H-NMR spectroscopy-based metabolite profiling of human cancer cell lines and response to chemotherapy.

Bayet-Robert M, Loiseau D, Rio P, Demidem A, Barthomeuf C, Stepien G, Morvan D.

Magn Reson Med. 2010 May;63(5):1172-83. doi: 10.1002/mrm.22303.

9.

A model of phospholipid biosynthesis in tumor in response to an anticancer agent in vivo.

Behzadi M, Demidem A, Morvan D, Schwartz L, Stepien G, Steyaert JM.

J Integr Bioinform. 2010 Mar 25;7(3). doi: 10.2390/biecoll-jib-2010-129.

PMID:
20375456
11.

Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy.

Loiseau D, Morvan D, Chevrollier A, Demidem A, Douay O, Reynier P, Stepien G.

Mol Carcinog. 2009 Aug;48(8):733-41. doi: 10.1002/mc.20539.

PMID:
19347860
12.

Optimal methionine-free diet duration for nitrourea treatment: a Phase I clinical trial.

Durando X, Thivat E, Farges MC, Cellarier E, D'Incan M, Demidem A, Vasson MP, Barthomeuf C, Chollet P.

Nutr Cancer. 2008;60(1):23-30. doi: 10.1080/01635580701525877.

PMID:
18444132
13.
14.
15.

A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer.

Thivat E, Durando X, Demidem A, Farges MC, Rapp M, Cellarier E, Guenin S, D'Incan M, Vasson MP, Chollet P.

Anticancer Res. 2007 Jul-Aug;27(4C):2779-83.

17.
20.
22.
24.
25.

Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.

Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, Trevisan C, Taylor J, Detels R, Martínez-Maza O.

Clin Immunol. 1999 Nov;93(2):114-23.

PMID:
10527687
26.

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.

Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B.

Cancer Biother Radiopharm. 1997 Jun;12(3):177-86.

PMID:
10851464
27.

Sensitization of AIDS related non-Hodgkin's B lymphoma cell lines to cytotoxic drugs toxins by interferon-gamma.

Demidem A, Salahuddin Z, Lam T, Levine A, Khan R, Hober D, Bonavida B.

Int J Oncol. 1996 Mar;8(3):461-8.

PMID:
21544383
28.

In vitro T cell response to staphylococcal enterotoxin B superantigen in chronic plaque type psoriasis.

Bour H, Demidem A, Garrigue JL, Krasteva M, Schmitt D, Claudy A, Nicolas JF.

Acta Derm Venereol. 1995 May;75(3):218-21.

29.

Establishment of nickel-specific T cell lines from patients with allergic contact dermatitis: comparison of different protocols.

Bour H, Nicolas JF, Garrigue JL, Demidem A, Schmitt D.

Clin Immunol Immunopathol. 1994 Oct;73(1):142-5.

PMID:
7923911
30.
31.

[Bias of index of T-lymphocytes and chronic inflammatory dermatoses].

Michalaki H, Nicolas JF, Bour H, Demidem A, Schmitt D.

Pathol Biol (Paris). 1994 Mar;42(3):254-61. Review. French.

PMID:
8090576
32.

The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin.

Rizova H, Nicolas JF, Morel P, Kanitakis J, Demidem A, Revillard JP, Wijdenes J, Thivolet J, Schmitt D.

J Dermatol Sci. 1994 Feb;7(1):1-13.

PMID:
8193079
33.

Contact sensitivity in mice: differential effect of vitamin D3 derivative (calcipotriol) and corticosteroids.

Garrigue JL, Nicolas JF, Demidem A, Bour H, Viac J, Thivolet J, Schmitt D.

Clin Immunol Immunopathol. 1993 May;67(2):137-42.

PMID:
8519089
34.

CD4 antibody therapy and cyclosporin A differentially affect HLA-DR and ICAM-1 expression in psoriatic skin.

Nicolas JF, Rizova H, Demidem A, Thivolet J, Morel P, Revillard JP.

J Invest Dermatol. 1992 Jun;98(6):943-4. No abstract available.

35.

Effects of chloroquine on antigen-presenting functions of epidermal cells from normal and psoriatic skin.

Demidem A, Taylor JR, Grammer SF, Streilein JW.

J Invest Dermatol. 1992 Feb;98(2):181-6.

37.
38.

Functional dichotomy between Langerhans cells that present antigen to naive and to memory/effector T lymphocytes.

Streilein JW, Grammer SF, Yoshikawa T, Demidem A, Vermeer M.

Immunol Rev. 1990 Oct;117:159-83. Review.

PMID:
2258190
39.

Dissociation of antigenicity and immunogenicity of neonatal epidermal allografts in the mouse.

Demidem A, Chiller JM, Kanagawa O.

Transplantation. 1990 May;49(5):966-71.

PMID:
2336712
40.

Influence of microenvironmental factors on human Langerhans cell function in vitro.

Demidem A, Taylor JR, Grammer SF, Streilein JW.

Reg Immunol. 1990-1991;3(6):297-304.

PMID:
2151920
41.

Structure, function, and immunogenicity of human insulinoma cells.

Thivolet CH, Demidem A, Haftek M, Durand A, Bertrand J.

Diabetes. 1988 Sep;37(9):1279-86.

PMID:
2457530
42.
43.

Lympho-epidermal interactions in patients receiving human Langerhans cell free cultured epidermal allografts as a skin substitute.

Demidem A, Faure M, Mauduit G, Rimokh R, Thivolet J.

J Dermatol. 1988 Apr;15(2):104-10. No abstract available.

PMID:
2459171
44.

Expression of class I-MHC antigens by cultured human epidermis and epidermal allografts.

Mauduit G, Vincent C, Gielen V, Faure M, Demidem A, Thivolet J.

Tissue Antigens. 1987 Feb;29(2):65-70.

PMID:
3299871
45.

Growth and differentiation of human epidermal cultures used as auto- and allografts in humans.

Faure M, Mauduit G, Schmitt D, Kanitakis J, Demidem A, Thivolet J.

Br J Dermatol. 1987 Feb;116(2):161-70.

PMID:
2435313
46.

Expression of blood group antigens by cultured human epidermal cells used as allografts.

Mauduit G, Ohrt C, Faure M, Kanitakis J, Demidem A, Thivolet J.

Acta Derm Venereol. 1987;67(2):93-9.

PMID:
2438890
47.

Expression of blood group antigens by cultured epidermal cells.

Mauduit GB, Faure MR, Demidem A, Thivolet J, Herriot HE.

J Invest Dermatol. 1986 Dec;87(6):798. No abstract available.

48.

Long-term survival and immunological tolerance of human epidermal allografts produced in culture.

Thivolet J, Faure M, Demidem A, Mauduit G.

Transplantation. 1986 Sep;42(3):274-80.

PMID:
3750385
49.

[Human epidermis grown in in vitro culture is not rejected and may be used as a skin allograft].

Thivolet J, Faure M, Demidem A, Mauduit G.

Bull Acad Natl Med. 1986 Apr;170(4):557-62. French. No abstract available.

PMID:
3536018
50.

Loss of allogeneic T-cell activating ability and Langerhans cell markers in human epidermal cell cultures.

Demidem A, Faure M, Dezutter-Dambuyant C, Thivolet J.

Clin Immunol Immunopathol. 1986 Mar;38(3):319-26.

PMID:
2935342

Supplemental Content

Loading ...
Support Center